Anti-Tick Vaccines Targeting the Tick, Not the Pathogen

Most vaccine research against tick-borne disease targets the pathogen — the Lyme bacterium, the tick-borne encephalitis virus, the rickettsiae. An anti-tick vaccine does the opposite. It targets proteins that belong to the tick itself, on the logic that a tick which cannot feed efficiently is a tick that cannot transmit whatever it carries. A 2025 review framed the logic directly: "Anti-tick vaccines present a promising option to lower tick populations and the incidence of TBDs by specifically targeting tick feeding, reproduction, and development" (Elsevier 2025), operating "via antigen-specific antibodies that interfere with the functionality of tick proteins and other immune mechanisms" (Elsevier 2025). The same review drew the contrast with pathogen-directed immunization: "While anti-tick vaccines target the vector ecology, anti-pathogen vaccines directly neutralize TBPs (e.g., Borrelia burgdorferi, TBEV) by inducing pathogen-specific immunity." (Elsevier 2025)

The appeal of the anti-tick approach is that a single vaccine, if it worked, would not need to specify the pathogen in advance. The 2018 HHS Tick-Borne Disease Working Group Report to Congress described the window during which such a vaccine would act:

"Anti-Tick Vaccines for Humans: Another Area of Promise Tick feeding is a slow, multi-stage process that begins with a bite and ends a few days later with full engorgement of the tick. The pathogen that causes Lyme disease resides in the tick’s gut prior to a blood meal. After tick feeding has begun, the pathogen migrates to the tick’s salivary glands, and the tick injects salivary gland antigens into its host. Ticks are most vulnerable during the blood meal. For that reason, the ideal anti-tick vaccine would interfere with tick physiology during feeding or prevent feeding altogether. An advantage of such an approach is that it could theoretically prevent transmission of Lyme disease, anaplasmosis, and babesiosis, and potentially other tick-borne infections by interruption of tick feeding. Most pathogens that are transmitted by the Ixodes species of tick usually require more than 24 hours of feeding to infect a host." — HHS, 2018, pp. 32–33. Tick-Borne Disease Workin...

The idea is old. A 2022 HHS subcommittee report traced the lineage: "More than 80 years ago, the potential for developing an anti-tick vaccine was established when guinea pigs immunized by intracutaneous administration of an extract of American dog tick (D. variabilis) larvae rejected up to 100% of a larval challenge." (HHS 2022) From that point onward, work on anti-tick vaccines progressed, "in large part due to advances achieved in characterizing multiple aspects of tick physiology and tick-host interactions at the cellular, molecular, and genomic levels" (HHS 2022). The same report named the persistent obstacle: "a significant impediment to anti-tick vaccine development and understanding the tick-host-pathogen interface is the inability to link specific tick saliva molecules with specific biological activities" (HHS 2022). And the candid assessment of field performance: "With a few notable exceptions, the majority of anti-tick vaccination experiments achieved partial protection that would be insufficient to provide sufficient protection against infestation and tick-borne pathogen transmission in the field." (HHS 2022)

The historical reference point: Bm86

The one commercialized anti-tick vaccine is a veterinary product, not a human one. It targets a cattle tick, Rhipicephalus microplus, and the antigen is a midgut protein named Bm86. A 2025 MDPI review described the product line: "Vaccination against ticks, specifically R. microplus, using Bm86-based vaccines such as TickGARD™ and Gavac™, has shown significant efficacy in reducing tick infestations and the incidence of tick-borne diseases." (MDPI 2025) The same review noted the mechanism: "These vaccines, which induce an immune response that damages engorging ticks, serve as an effective complement to chemical control measures" (MDPI 2025). Separately, a 2025 MDPI survey of recombinant-protein tick vaccines reported the outcome measure: "Recombinant protein vaccines, such as those based on Bm86 from the midgut of R. microplus, have shown significant efficacy by reducing tick infestations and decreasing the transmission of pathogens like B. bovis and A. marginale in cattle" (MDPI 2025).

Bm86 did not generalize. A 2024 MDPI comprehensive review of anti-tick vaccines noted what followed: "Another midgut protein from R. microplus, Bm95, was extensively studied initially in response to the lack of efficiency of the commercially available Bm86-based vaccine against specific strains." (MDPI 2024) That single sentence contains the practical lesson of the Bm86 program: a vaccine that worked against one strain of one tick did not automatically work against other strains, and certainly not against other tick species or pathogens.

The protein categories under study

With Bm86 as reference, subsequent research has expanded across several protein families, organized by where in the tick they are expressed and what they do during feeding. The 2025 review framed the hunt: "The main obstacle to the development of effective vaccines is the identification of immunoprotective antigens." (Elsevier 2025) Candidate antigens cluster in four tissues: "Several tick tissue-derived antigen candidates have shown promise, including those derived from tick salivary glands, midgut, cement, and egg-associated antigens." (Elsevier 2025)

Salivary-gland proteins. The 2024 MDPI review described one salivary-protein study targeting Amblyomma sculptum (the primary vector of Rocky Mountain spotted fever in Brazil): "Three protein candidates, namely, AsKunitz, As8.9kDa, and AsBasicTail, derived from Amblyomma sculptum, the primary vector of Rickettsia rickettsi in Brazil, were used for immunization of mice." (MDPI 2024) The reported result: "This resulted in a high percentage of efficacy against female ticks (up to 85%), and the mortality rate of nymphs feeding on immunized mice reached 70–100%." (MDPI 2024) A separate vaccine strategy used salivary proteins from Ixodes scapularis (black-legged tick or deer tick): "Ixodes scapularis tick histamine release factor (tHRH), tick salivary lectin pathway inhibitor (TSLPI) and tick inhibitor of factor Xa toward factor V (TIX-5) have demonstrated the ability to reduce engorgement in vaccinated cattle and B. borrelia transmission in rabbit immunized with the recombinant proteins." (MDPI 2024) The same study recorded a format dependency: "However, a similar experiment using DNA did not offer protection or prevent pathogen transmission, emphasizing the crucial role of the antigen format used" (MDPI 2024).

Subolesin and Akirin. One family of candidates has shown cross-species efficacy. The 2024 MDPI review described the target: "proteins like subolesin (SUB), the tick ortholog of vertebrate Akirin, have been extensively explored as potential vaccine candidates" (MDPI 2024). On results: "SUB, found across various tick species, has shown promise in vaccination efforts, such as in cattle, conferring protective effects against multiple ticks and pathogen transmission" (MDPI 2024). The efficacy range reported, against a benchmark of well-known antigens: "Vaccines utilizing SUB, either alone or combined with other antigens, have demonstrated efficacy ranging from 80% to 97%, comparable to or surpassing that of well-known tick antigens like Bm86, metalloprotease, ribosomal protein P0, ferritin 2, and aquaporin" (MDPI 2024).

Cement proteins. The 2024 review described a second antigen route — the glue a tick secretes to attach: "Tick cement, a blend of glyco- and lipoproteins secreted into the host during tick attachment, serves as a valuable reservoir of tick-derived antigens for vaccine development." (MDPI 2024) The same review noted that cement is not inert residue: "Apart from securing tick mouthparts to the host skin, tick cement also acts as a storage site for pathogens like B. burgdorferi sensu lato and TBEV." (MDPI 2024) One cement-derived candidate, 64P from Rhipicephalus appendiculatus, was reported to act across multiple species in preclinical trials: "One notable antigen, 64P (64TRPs), a 15 kDa cement protein secreted by Rhipicephalus appendiculatus salivary glands, has shown cross-protection against different tick species, including Rhipicephalus sanguineus and Ixodes ricinus." (MDPI 2024)

Broader candidate landscape. The 2025 review named the candidates on the current list: "Overall, several notable candidates, including MPs, SUB, serpins, ribosomal protein P0, and ferritin proteins such as FER1, FER2, and aquaporins, have demonstrated varying levels of efficacy in mitigating tick infestations and restricting the transmission of associated pathogens." (Elsevier 2025) Several candidates combined into single formulations — "cocktail vaccines" — are also under study: "It has been proposed that a combination of candidate antigens (cocktail vaccines) may confer enhanced efficacy in developing an efficacious tick vaccine." (Elsevier 2025)

The mRNA approach: tick saliva as a 19-protein cocktail

One study has drawn particular attention for combining the anti-tick approach with mRNA vaccine technology. The 2022 HHS subcommittee report described the work — including a qualification about how the results should be read:

"The recent report by Sajid et al. (2021) incorporated an mRNA vaccination platform with multiple blacklegged tick antigens to induce resistance in the guinea pig to both infestation and pathogen transmission similar to classically acquired tick resistance. Sajid et al. (2021) incorporated 19 blacklegged tick salivary proteins into a nucleoside modified mRNA lipid particle, nano-encapsulated vaccine formulation, well beyond the number of epitopes used in prior studies, to successfully mimic the acquired tick resistance response. However, interpretation of the findings reported by Sajid et al. (2021) regarding blocking tick transmission of the Lyme disease agent, Borrelia burgdorferi, are more nuanced than they initially appear due to experimental design considerations in the timing of removing ticks, and longer attachment resulted in effective pathogen transmission." — HHS, 2022. Changing Dynamics of Tick...

The logic of inducing an itch-and-grooming response has a basis in earlier work the same report cites: "Researchers have sought to identify tick saliva molecules that could be used in vaccination to induce a resistance or itching response." (HHS 2022) But the same report is direct about how the broader class has performed: "Results to date of anti-tick vaccination efforts with single and, in some cases, multiple tick-derived antigens have been highly variable and largely incompatible with blocking tick feeding and pathogen transmission at a level that would be commercially viable" (HHS 2022). And it poses the design question that follows from the itch mechanism: "A question yet to be answered is what amount of cutaneous inflammation and itch at the bite site would be acceptable in an anti-tick vaccine licensed for human use." (HHS 2022)

Alternative delivery formats

Protein injection is not the only platform being tested. The 2024 review described DNA vaccines: "Many research groups have extensively explored DNA vaccines to control tick infestation. These vaccines, distinct from traditional protein-based ones, encode antigenic proteins within bacterial plasmids controlled by eukaryotic promoters." (MDPI 2024) The mechanism: "They introduce plasmid DNA into cells, residing as episomal DNA within the nucleus to continuously generate protective antigens throughout the cell’s lifespan." (MDPI 2024) One reported finding: "Key research includes Sayed et al.’s study, where DNA from Argas persicus eggs used to immunize chickens reduced tick feeding by up to 89.39%." (MDPI 2024)

A second platform uses viral vectors: "Viral vector vaccines use viruses as delivery systems to express target antigens within host cells, intending to trigger an immune response against them." (MDPI 2024) The practical advantage for wildlife-directed programs is delivery: "Oral delivery holds potential for developing bait vaccines targeting wild animals like rodents or other small reservoir hosts involved in the transmission of tick-borne pathogens." (MDPI 2024) A 2024 review described one specific proof-of-concept: "A.J. Ullmann et al. explored the potential of adenoviral-vectored proteins in eliciting an immune response against Ixodes scapularis ticks and Lyme borreliosis. Their findings suggest that vaccinating with tick salivary proteins (SALP) via an adenoviral vector can effectively modulate a Th1 response in the host and partially control spirochete load in vaccinated mice following an infected tick challenge." (MDPI 2024)

Where things sit for humans

None of this research has yet produced an anti-tick vaccine approved for human use. The 2021 Eisen and colleagues barriers-to-tick-management review in the Journal of Medical Entomology stated the current state plainly: "No such vaccines are currently available for use in humans against any North American tick species or tick-borne pathogen, although there are several canine Lyme disease vaccines on the market." (JME 2021) The same paper described the research-and-development interest: "There also is considerable interest in anti-tick vaccines, with potential for blocking transmission of multiple pathogens transmitted by the same or multiple tick species" (JME 2021). And its conclusion, in one sentence: "However, the potential for such anti-tick vaccines to emerge as public health products is still unclear." (JME 2021)

The 2020 IDSA-AAN-ACR Clinical Practice Guidelines for Lyme disease offered the same framing from the clinical-guideline side: "Such knowledge is providing opportunities to explore additional immunization strategies to prevent transmission, including anti-tick vaccines, which may result in the prevention of multiple tick-borne diseases" (IDSA 2020).

In 2022, the HHS subcommittee on disease prevention and treatment endorsed the direction as a priority action: "Potential Action 3.1: Increase development of “anti-tick” human vaccines and novel tick-control methods to provide protection against multiple tick-borne diseases." (HHS 2022) The rationale emphasized the single-vaccine-multiple-diseases logic: "Anti-tick vaccines are an intriguing approach that could prevent multiple tick-borne conditions with a single vaccine. This approach could be considered one of creating “tick resistance” in humans by vaccinating with tick salivary or other factors to induce an anti-tick immune response." (HHS 2022) And it pointed to a specific disease where a clinical trial might be feasible: "Given the remarkable rise in AGS cases, powering a clinical trial for AGS anti-tick vaccine would be feasible." (HHS 2022)

Wildlife-directed vaccines as a parallel track

A separate research line does not target humans at all. It targets white-tailed deer, the main reproductive host for the adult stage of several tick species. The 2022 HHS subcommittee report described the rationale: "Deer-targeted anti-tick vaccines are a promising tool with the potential to control ticks on these hosts. They are more environmentally and socially acceptable and have fewer non-target consequences." (HHS 2022) The practical challenge: "However, white-tailed deer are challenging to work with. There has been a lot of research to identify antigenic targets in laboratory animal systems, but proteins expressed by ticks on lab animals are not necessarily the same as those expressed in ticks feeding on deer and may not be the same between tick species; thus, there is a need for the identification of new tick antigens." (HHS 2022)

A separate portion of the same report noted that such programs are not starting from zero: "Wildlife- and livestock-directed oral anti-tick vaccines are being developed, but an important consideration is that additional oral vaccines exist for white-tailed deer (such as tuberculosis and chronic wasting disease vaccines). Development of a deer anti-tick vaccine is an achievable objective." (HHS 2022)

A note on scope

Anti-tick vaccines are one branch of the broader vaccine effort against tick-borne disease; anti-pathogen vaccines (for the Lyme disease bacterium, for tick-borne encephalitis virus, for Rickettsia species) are a different branch, evaluated in other articles in this section — see, for example, the Lyme vaccine development pipeline and VLA15 Phase 3. The 2024 MDPI review placed the anti-tick approach alongside acaricides and environmental controls rather than alongside pathogen-specific immunization: "In the context of a comprehensive tick management strategy, the development of anti-tick vaccines targeting tick-borne pathogen reservoirs is acknowledged as a promising approach. These vaccines aim to block the transmission of pathogens to other hosts, including humans, thereby enhancing control measures against ticks." (MDPI 2024) That framing — tick management, not human immunization — is the one the field's cited sources consistently use. The absence of a licensed human product, after eighty years of research, is the headline of the current state of the science.